Levofloxacin (Tavanic) in Complex Therapy of Tuberculosis
Abstract
Preclinical and clinical investigations of levofloxacin in complex with antituberculosis drugs of the main and reserve groups in 152 patients with newly diagnosticated drug resistant pulmonary tuberculosis demonstrated its efficacy and safety. The adverse events due to levofloxacin (8.6% of the cases) disappeared after discontinuation of the drug use without any affection of the patient's organs. Levofloxacin is applicable in antituberculosis therapy of patients with extended, acute progressing or polycavernous tuberculosis of the lungs. It provides significant clinical improvement and if necessary allows to prepare the patient in a short period for surgical operation.
About the Authors
G. B. Sokolova
Research Institute of Phthisiopulmonology, I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
A. D. Kunichan
Research Institute of Phthisiopulmonology, I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
YA. V. Lazareva
Research Institute of Phthisiopulmonology, I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
References
1. Schito G.C., Debbia E.A., Marchese A.A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46: Topic T 1: 3-9.
2. Яковлев С.В., Яковлев В.П. Применение левофлоксацина при лечении инфекции дыхательных путей. Антибиотики и химиотер. 2002; 8: 32-42.
3. Simpson I.N., Harding I. Levofloxacin review of tolerability and safety. Intern J Antimicrob Agents 2001; 17: Suppl 1.
Review
For citations:
Sokolova G.B., Kunichan A.D., Lazareva Ya.V. Levofloxacin (Tavanic) in Complex Therapy of Tuberculosis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2009;54(1-2):31-37. (In Russ.)
Views:
1659
Email this article 